Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.32 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.32 |
| ▸ | SMO | Q99835 | 2/20 | 0.31 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31336704 | 1.00 | SMYD2 (0.37) | SMYD2HSD11B1ELANECTSGPRTN3 | |
| SCHEMBL31372538 | 0.80 | SMYD2 (0.39) | SMYD2HSD11B1ELANESMOEHMT2 | |
| SCHEMBL31372647 | 0.80 | SMYD2 (0.39) | SMYD2HSD11B1ELANESMOEHMT2 | |
| SCHEMBL31336836 | 0.78 | SMYD2 (0.36) | SMYD2 | |
| SCHEMBL31336713 | 0.78 | SMYD2 (0.36) | SMYD2 | |
| SCHEMBL31336845 | 0.78 | SMYD2 (0.35) | SMYD2 | |
| SCHEMBL31336758 | 0.78 | SMYD2 (0.35) | SMYD2 | |
| SCHEMBL31336626 | 0.78 | SMYD2 (0.35) | SMYD2 | |
| SCHEMBL18961289 | 0.77 | SMYD2 (0.38) | SMYD2HSD11B1SMOEHMT2 | |
| SCHEMBL31336878 | 0.74 | SMO (0.36) | HSD11B1ELANECTSGPRTN3SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688154-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - Portela & Ca., S.A. (PT) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025023851-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | disclosed |